These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 27853999)

  • 1. Quantifying the Exposure of Tapentadol Extended Release in Japanese Patients with Cancer Pain and Bridging Tapentadol Pharmacokinetics Across Populations Using a Modeling Approach.
    Zhang L; Yan X; Nobe S; Zannikos P; Etropolski M; Nandy P
    Clin Drug Investig; 2017 Mar; 37(3):273-283. PubMed ID: 27853999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetic Modeling of Tapentadol Extended Release (ER) in Healthy Subjects and Patients with Moderate or Severe Chronic Pain.
    Huntjens DR; Liefaard LC; Nandy P; Drenth HJ; Vermeulen A
    Clin Drug Investig; 2016 Mar; 36(3):213-23. PubMed ID: 26798023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain.
    Xu XS; Smit JW; Lin R; Stuyckens K; Terlinden R; Nandy P
    Clin Pharmacokinet; 2010 Oct; 49(10):671-82. PubMed ID: 20818833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects.
    Zannikos PN; Smit JW; Stahlberg HJ; Wenge B; Hillewaert VM; Etropolski MS
    J Opioid Manag; 2013; 9(4):291-300. PubMed ID: 24353023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain.
    Imanaka K; Tominaga Y; Etropolski M; van Hove I; Ohsaka M; Wanibe M; Hirose K; Matsumura T
    Curr Med Res Opin; 2013 Oct; 29(10):1399-409. PubMed ID: 23937387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials.
    Etropolski M; Kuperwasser B; Flügel M; Häufel T; Lange B; Rauschkolb C; Laschewski F
    Adv Ther; 2014 Jun; 31(6):604-20. PubMed ID: 24985410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.
    Imanaka K; Tominaga Y; Etropolski M; Ohashi H; Hirose K; Matsumura T
    Clin Drug Investig; 2014 Jul; 34(7):501-11. PubMed ID: 24906437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose conversion between tapentadol immediate and extended release for low back pain.
    Etropolski MS; Okamoto A; Shapiro DY; Rauschkolb C
    Pain Physician; 2010; 13(1):61-70. PubMed ID: 20119464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial.
    Buynak R; Rappaport SA; Rod K; Arsenault P; Heisig F; Rauschkolb C; Etropolski M
    Clin Ther; 2015 Nov; 37(11):2420-38. PubMed ID: 26428249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathy.
    Schwartz S; Etropolski MS; Shapiro DY; Rauschkolb C; Vinik AI; Lange B; Cooper K; Van Hove I; Haeussler J
    Clin Drug Investig; 2015 Feb; 35(2):95-108. PubMed ID: 25503082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations.
    Göhler K; Brett M; Smit JW; Rengelshausen J; Terlinden R
    Int J Clin Pharmacol Ther; 2013 Apr; 51(4):338-48. PubMed ID: 23357834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back pain.
    Biondi DM; Xiang J; Etropolski M; Moskovitz B
    J Opioid Manag; 2015; 11(5):393-403. PubMed ID: 26535967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial.
    Schwartz S; Etropolski M; Shapiro DY; Okamoto A; Lange R; Haeussler J; Rauschkolb C
    Curr Med Res Opin; 2011 Jan; 27(1):151-62. PubMed ID: 21162697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study.
    Afilalo M; Etropolski MS; Kuperwasser B; Kelly K; Okamoto A; Van Hove I; Steup A; Lange B; Rauschkolb C; Haeussler J
    Clin Drug Investig; 2010; 30(8):489-505. PubMed ID: 20586515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain.
    Coluzzi F; Ruggeri M
    Curr Med Res Opin; 2014 Jun; 30(6):1139-51. PubMed ID: 24528146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of tapentadol ER for managing moderate to severe chronic pain.
    Afilalo M; Morlion B
    Pain Physician; 2013 Jan; 16(1):27-40. PubMed ID: 23340531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study.
    Buynak R; Shapiro DY; Okamoto A; Van Hove I; Rauschkolb C; Steup A; Lange B; Lange C; Etropolski M
    Expert Opin Pharmacother; 2010 Aug; 11(11):1787-804. PubMed ID: 20578811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy.
    Vinik AI; Shapiro DY; Rauschkolb C; Lange B; Karcher K; Pennett D; Etropolski MS
    Diabetes Care; 2014 Aug; 37(8):2302-9. PubMed ID: 24848284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of blood pressure and heart rate in patients with hypertension who received tapentadol extended release for chronic pain: a post hoc, pooled data analysis.
    Biondi DM; Xiang J; Etropolski M; Moskovitz B
    Clin Drug Investig; 2014 Aug; 34(8):565-76. PubMed ID: 24916058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic Analysis, Analgesic Effects, and Adverse Effects of Tapentadol in Cancer Patients with Pain.
    Homma M; Kokubun H; Okuwaki K; Katada C; Hayashi N; Kanai A; Koizumi W; Atsuda K
    Biol Pharm Bull; 2020; 43(6):1000-1006. PubMed ID: 32475909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.